NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions – Adds New U.S. Patent to Portfolio
- Wednesday, February 22, 2023, 7:02
- Finance
- Add a comment
Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality; This new patent represents a third patent family, that now totals 48 issued…
About the Author
adminasapcorp has written 41552 stories on this site.